ArticleNature communications2021
The E3 ubiquitin ligase component, Cereblon, is an evolutionarily conserved regulator of Wnt signaling.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 40 citations in OpenAlex.
- Safety considerations for cereblon-recruiting targeted protein degraders.Nature reviews. Drug discovery · 2026Review
- Review
- Targeted protein degradation for fetal hemoglobin induction: a new paradigm in β-hemoglobinopathy therapy.Biomarker research · 2026Review
- Hydrogen/Deuterium Exchange for Chiral Stability Assessment in Acidic Methine-Containing Compounds.Analytical chemistry · 2025Article
- [IKZF3/Aiolos and tumors].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025Review
- Allostery in Disease: Anticancer Drugs, Pockets, and the Tumor Heterogeneity Challenge.Journal of molecular biology · 2025Review
- Controlling CRISPR-Cas9 genome editing in human cells using a molecular glue degrader.Molecular therapy. Nucleic acids · 2025Article
- Ubiquitination in cancer: mechanisms and therapeutic opportunities.Cancer communications (London, England) · 2025Review
- Advances in the structures, mechanisms and targeting of molecular chaperones.Signal transduction and targeted therapy · 2025Review
- Cullin-RING ligase BioE3 reveals molecular-glue-induced neosubstrates and rewiring of the endogenous Cereblon ubiquitome.Cell communication and signaling : CCS · 2025Article
- Safety and effectiveness of lenalidomide in Japanese patients with relapsed/refractory ATLL: post-marketing surveillance.International journal of hematology · 2025Article
- Predicting PROTAC off-target effects via warhead involvement levels in drug-target interactions using graph attention neural networks.Computational and structural biotechnology journal · 2025Article
- CRBN modulates synuclein fibrillation via degradation of DNAJB1 in mouse model of Parkinson disease.NPJ Parkinson's disease · 2024Article
- Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy.Journal of hematology & oncology · 2024Review
- The cross talk of ubiquitination and chemotherapy tolerance in colorectal cancer.Journal of cancer research and clinical oncology · 2024Review
- Cereblon influences the timing of muscle differentiation inProceedings of the National Academy of Sciences of the United States of America · 2023Article
- Fragment Linker Prediction Using the Deep Encoder-Decoder Network for PROTACs Drug Design.Journal of chemical information and modeling · 2023Article
- Life mimics art.Cell research · 2023Article
- Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse.Current oncology (Toronto, Ont.) · 2023Review
- Lenalidomide in Multiple Myeloma: Review of Resistance Mechanisms, Current Treatment Strategies and Future Perspectives.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 5 institutions in 1 country.
Chen Shen *Molecular Oncology Program, The DeWitt Daughtry Family Department of Surgery, Miller School of Medicine, University of Miami, Miami, FL, USA.
Anmada Nayak *Molecular Oncology Program, The DeWitt Daughtry Family Department of Surgery, Miller School of Medicine, University of Miami, Miami, FL, USA.
Leif R NeitzelDepartment of Medicine, University of Maryland, Baltimore, MD, USA.
Amber A AdamsDepartment of Molecular and Systems Biology and the Norris Cotton Cancer Center, Geisel School of Medicine, Dartmouth College, Hanover, NH, USA.
Maya Silver-IsenstadtDepartment of Medicine, University of Maryland, Baltimore, MD, USA.
Leah M SawyerDepartment of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, USA.
Hassina BenchabaneDepartment of Molecular and Systems Biology and the Norris Cotton Cancer Center, Geisel School of Medicine, Dartmouth College, Hanover, NH, USA.
Huilan WangMolecular Oncology Program, The DeWitt Daughtry Family Department of Surgery, Miller School of Medicine, University of Miami, Miami, FL, USA.
Nawat BunnagDepartment of Molecular and Systems Biology and the Norris Cotton Cancer Center, Geisel School of Medicine, Dartmouth College, Hanover, NH, USA.
Bin LiMolecular Oncology Program, The DeWitt Daughtry Family Department of Surgery, Miller School of Medicine, University of Miami, Miami, FL, USA.
Daniel T WynnMolecular Oncology Program, The DeWitt Daughtry Family Department of Surgery, Miller School of Medicine, University of Miami, Miami, FL, USA.
Fan YangMolecular Oncology Program, The DeWitt Daughtry Family Department of Surgery, Miller School of Medicine, University of Miami, Miami, FL, USA.
Marta Garcia-ContrerasMolecular Oncology Program, The DeWitt Daughtry Family Department of Surgery, Miller School of Medicine, University of Miami, Miami, FL, USA.ORCID 0000-0001-8014-7966
Charles H WilliamsDepartment of Medicine, University of Maryland, Baltimore, MD, USA.
Sivanesan DakshanamurthyDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
Charles C HongDepartment of Medicine, University of Maryland, Baltimore, MD, USA.ORCID 0000-0002-0424-8252
Nagi G AyadDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
Anthony J CapobiancoMolecular Oncology Program, The DeWitt Daughtry Family Department of Surgery, Miller School of Medicine, University of Miami, Miami, FL, USA.ORCID 0000-0002-3706-6797
Yashi AhmedDepartment of Molecular and Systems Biology and the Norris Cotton Cancer Center, Geisel School of Medicine, Dartmouth College, Hanover, NH, USA.
Ethan LeeDepartment of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, USA.
David J RobbinsMolecular Oncology Program, The DeWitt Daughtry Family Department of Surgery, Miller School of Medicine, University of Miami, Miami, FL, USA. dr956@georgetown.edu.ORCID 0000-0003-0190-2973
University of Miami · USDartmouth College · USUniversity of Maryland, Baltimore · USVanderbilt University · USGeorgetown University · US
Funding
Tumor Biology Research ProgramP30CA240139 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Daniel Bilbao · 2019 to 2026
$24.1MInterdisciplinary Training Program Muscle BiologyT32AR007592 · NIAMS · UNIVERSITY OF MARYLAND BALTIMORE · PI Aikaterini Kontrogianni-Konstantopoulos · 1996 to 2026
$11.7MMechanism of Wnt signal transductionR35GM122516 · NIGMS · VANDERBILT UNIVERSITY · PI ETHAN LEE · 2017 to 2026
$5.8MGenetic and Molecular Dissection of Wnt Pathway ActivationSupplementR35GM136233 · NIGMS · DARTMOUTH COLLEGE · PI Yasmath Ahmed · 2020 to 2026
$4.5MInhibition of the Wnt Receptor Complex by the Tumor Suppressor Adenomatous Polyposis ColiR01CA244188 · NCI · DARTMOUTH COLLEGE · PI AHMED, YASMATH, LEE, ETHAN · 2020 to 2024
$3.2MChemical Genetic Analysis of Vertebrate DevelopmentR01GM118557 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HONG, CHARLES C · 2016 to 2019
$2.0MTargeting Wnt-dependent colorectal cancerR01CA219189 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI ROBBINS, DAVID J · 2018 to 2022
$1.9MRole of ADP-ribosylation in Wnt Pathway ActivationR01GM121421 · NIGMS · DARTMOUTH COLLEGE · PI AHMED, YASMATH · 2017 to 2019
$1.1MAPC Tumor Suppressor in Cell Differentiation and DeathR01GM122222 · NIGMS · DARTMOUTH COLLEGE · PI AHMED, YASMATH · 2017 to 2019
$977kNCI NIH HHS P30 CA240139NCI NIH HHS R01 CA219189NCI NIH HHS R01 CA244188NIAMS NIH HHS T32 AR007592NIGMS NIH HHS R01 GM118557NIGMS NIH HHS R01 GM121421NIGMS NIH HHS R01 GM122222NIGMS NIH HHS R35 GM122516NIGMS NIH HHS R35 GM136233
Abstract
Immunomodulatory drugs (IMiDs) are important for the treatment of multiple myeloma and myelodysplastic syndrome. Binding of IMiDs to Cereblon (CRBN), the substrate receptor of the CRL4
Indexed as
Adaptor Proteins, Signal TransducingAnimalsCasein Kinase IalphaDrosophila melanogasterDrosophila ProteinsEmbryo, NonmammalianEvolution, MolecularHEK293 CellsHumansImmunologic FactorsLenalidomideMiceOrganoidsPeptide HydrolasesUbiquitinationUbiquitin-Protein LigasesAdaptor Proteins, Signal TransducingCasein Kinase IalphaCRBN protein, humanCrbn protein, mouseCRBN protein, zebrafishDrosophila ProteinsImmunologic FactorsLenalidomidePeptide HydrolasesUbiquitin-Protein LigasesZebrafish Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.